Talk:Lornoxicam
Jump to navigation
Jump to search
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Lornoxicam.
|
Removed text
The following text was marked as original research and does not seem to be closely related to the article's topic:
- Three of the most commonly employed substrate probes for determining CYP2C9 activity in crude human tissue fractions are (S)-warfarin (7-hydroxylation), tolbutamide (methylhydroxylation), and diclofenac (4-hydroxylation). And the best in vivo probes for CYP2C9 activity are tolbutamide and flurbiprofen. Turnover of (S)-warfarin and tolbutamide by CYP2C9 is extremely slow. Conversely, diclofenac has the advantage that CYP2C9 catalyzes its metabolism with a high turnover number, but is not a useful in vivo probe for CYP2C9.
--ἀνυπόδητος (talk) 12:40, 17 December 2010 (UTC)
This text was part of a WP:NOT PAPERS sounding section ("We suggest lornoxicam as a good Probe for CYP2C9, both In Vitro and In Vivo..."). --ἀνυπόδητος (talk) 13:41, 17 December 2010 (UTC)